Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain; Michael J. Keating; Philip A. Thompson; Alessandra Ferrajoli; Jan A. Burger; Gautam Borthakur; Koichi Takahashi; Zeev Estrov; Nathan Fowler; Tapan M. Kadia; Marina Konopleva; Yesid Alvarado; Musa Yılmaz; Courtney D. DiNardo; Prithviraj Bose; Maro Ohanian; Naveen Pemmaraju; Elias Jabbour; Koji Sasaki; Rashmi Kanagal‐Shamanna; Keyur P. Patel; Jeffrey L. Jorgensen; Naveen Garg; Xuemei Wang; Katrina Sondermann; Nichole Cruz; Chongjuan Wei; Ana Ayala; William Plunkett; Hagop M. Kantarjian; Varsha Gandhi; William G. Wierda

doi:10.1056/nejmoa1900574

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL. (Funded by AbbVie and others; ClinicalTrials.gov number, NCT02756897.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jain et al. (2019) studied this question.

synapsesocial.com/papers/69d6ba7f8dca315383ed8af5 https://doi.org/10.1056/nejmoa1900574

View Full Paper

Ask AI

Bookmark

Share

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Ask about this paper

Abstract

Discussion

Cite This Study

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading